Home/Indications/Oncology/Renal Cell Carcinoma

Renal Cell Carcinoma

Oncology 8 original drugs

Novel Drugs

Reformulations

Drug Targets

Oncology indication. Renal Cell Carcinoma has 8 FDA-approved novel treatments, led by Bristol-Myers Squibb, with 308 active industry clinical trials across 34 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Renal Cell Carcinoma Market Leaders

Companies with the most FDA-approved novel Renal Cell Carcinoma drugs.

Phase 3 Readouts Pro

6 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q4 2026

Pazopanib

Xynomic Pharmaceuticals, Inc.

Estimated · stale NCT03592472

Q1 2027

Nivolumab

Bristol-Myers Squibb

Estimated · fresh NCT03873402

Q3 2027

—

Telix Pharmaceuticals (Innovations) Pty Limited

Estimated · fresh NCT07197580

Unlock 3 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Renal Cell Carcinoma Treatments by Mechanism

Top 9 mechanisms across 45 industry trials with a known mechanism of action.

See full pipeline →

Hypoxia-inducible Factor Inhibitor

7 trials 7 active 2 sponsors

Programmed Death Receptor-1 Blocking Antibody

22 trials 2 active 4 sponsors

AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3

5 trials 2 active 3 sponsors

ALK/ROS1/NTRK1/TRKB/TRKC

1 trials 1 active 1 sponsor

Kinase Inhibitor

6 trials 6 sponsors

Lymphocyte Growth Factor

1 trials 1 sponsor

Vascular Endothelial Growth Factor Inhibitor

1 trials 1 sponsor

RANK Ligand Inhibitor

1 trials 1 sponsor

Thalidomide Analog

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Renal Cell Carcinoma Clinical Pipeline by Phase

312 industry-sponsored trials across 157 sponsors

View full landscape →

Showing 8 of 8 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2020-05-11	NCT02982954
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2019-07-17	NCT03444766
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2018-03-19	NCT02596035
iOMEDICO AG	Everolimus	Kinase Inhibitor [EPC]	COMPLETED	2017-09-26	NCT01266837
iOMEDICO AG	Pazopanib	—	COMPLETED	2017-06-30	NCT01521715
Novartis	RAD001	—	COMPLETED	2017-06-06	NCT01206764
Novartis	Everolimus (RAD001)	—	COMPLETED	2016-04-01	NCT01514448
Novartis	Aldesleukin	Lymphocyte Growth Factor [EPC]	COMPLETED	2010-03-28	NCT00414765

Showing 37 of 37 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Xynomic Pharmaceuticals, Inc.	Pazopanib	—	RECRUITING	2026-12-30	NCT03592472
Telix Pharmaceuticals (Innovations) Pty Limited	—	—	RECRUITING	2027-08-31	NCT07197580
Arcus Biosciences, Inc.	Casdatifan	—	RECRUITING	2028-04	NCT07011719
Merck	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	RECRUITING	2032-02-27	NCT07227402
Telix Pharmaceuticals (Innovations) Pty Limited	89Zr-TLX250 PET/CT	—	RECRUITING	2026-06-30	NCT06750419
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2027-03-11	NCT03873402
AstraZeneca	Volrustomig	—	ACTIVE NOT RECRUITING	2030-02-21	NCT07000149
AstraZeneca	savolitinib	—	ACTIVE NOT RECRUITING	2025-12-31	NCT05043090
Bristol-Myers Squibb	Nivolumab and rHuPH20	—	ACTIVE NOT RECRUITING	2025-07-29	NCT04810078
Exelixis	XL092	—	ACTIVE NOT RECRUITING	2025-07	NCT05678673
Hutchmed	fruquintinib+sintilimab	—	ACTIVE NOT RECRUITING	2025-01	NCT05522231
Exelixis	Cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	ACTIVE NOT RECRUITING	2022-01-31	NCT03937219
Eisai Inc.	Lenvatinib	—	ACTIVE NOT RECRUITING	2020-08-28	NCT02811861
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2020-02-12	NCT03141177
Exelixis	Cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	NOT YET RECRUITING	2030-05-31	NCT07620574
AVEO Pharmaceuticals, Inc.	Tivozanib	—	COMPLETED	2026-01-20	NCT04987203
Telix Pharmaceuticals (Innovations) Pty Limited	—	—	COMPLETED	2022-10-20	NCT03849118
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2020-12-14	NCT03142334
Roche	Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody	—	COMPLETED	2020-02-14	NCT02420821
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2018-10-18	NCT02853331
Incyte Corporation	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2018-08-22	NCT03260894
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2017-06-26	NCT02231749
Novartis	pazopanib	—	COMPLETED	2015-10-15	NCT01235962
Immatics Biotechnologies GmbH	Sunitinib	—	COMPLETED	2015-07	NCT01265901
Exelixis	Cabozantinib tablets	—	COMPLETED	2015-05-22	NCT01865747
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2015-05-06	NCT01668784
AVEO Pharmaceuticals, Inc.	Tivozanib	—	COMPLETED	2014-07	NCT01076010
Novartis	Dovitinib	—	COMPLETED	2014-06	NCT01223027
AVEO Pharmaceuticals, Inc.	tivozanib (AV-951)	—	COMPLETED	2012-07	NCT01030783
Pfizer	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2012-04	NCT00631371
Heidelberg Pharma AG	124-Iodine-cG250 (124I-cG250)	—	COMPLETED	2009-11	NCT00606632
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	TERMINATED	2022-05-03	NCT03024996
Nektar Therapeutics	bempegaldesleukin	—	TERMINATED	2022-01-07	NCT03729245
Argos Therapeutics	Standard Treatment	—	TERMINATED	2018-04	NCT01582672
Lantheus Medical Imaging	piflufolastat F 18	—	WITHDRAWN	2027-09	NCT07084909
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	WITHDRAWN	2021-08-14	NCT03693573
Heidelberg Pharma AG	Iodine (124I) Girentuximab	—	WITHDRAWN	2018-12-01	NCT01762592

Showing 100 of 122 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
3D Medicines (Sichuan) Co., Ltd.	Lenvatinib + Envafolimab	—	RECRUITING	2026-12	NCT05024214
GI Innovation, Inc.	GI-108	—	RECRUITING	2027-02	NCT07172802
Neonc Technologies, Inc.	NEO212 Oral Capsule	—	RECRUITING	2027-02-28	NCT06047379
Beijing Biotech	EB-701/CA9-NK	—	RECRUITING	2027-04-14	NCT07551349
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-10516 + Lenvatinib	—	RECRUITING	2027-07-10	NCT07097935
Pfizer	PF-08634404	—	RECRUITING	2027-11-02	NCT07227415
Regeneron	REGN5678	—	RECRUITING	2027-11-15	NCT03972657
Advenchen Pharmaceuticals, LLC.	AL8326 40 mg	—	RECRUITING	2027-12	NCT05363280
7 Hills Pharma, LLC	Alintegimod	—	RECRUITING	2027-12-31	NCT06362369
A2 Biotherapeutics Inc.	A2B395	—	RECRUITING	2029-03-31	NCT06682793
AstraZeneca	AZD6750	—	RECRUITING	2029-10-02	NCT07115043
Bristol-Myers Squibb	Pumitamig	—	RECRUITING	2029-11-28	NCT07293351
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-8068；Adebrelimab ；Bevacizumab	—	RECRUITING	2030-12	NCT07239596
Merck	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	RECRUITING	2031-10-26	NCT07049926
Medicenna Therapeutics, Inc.	MDNA11	—	RECRUITING	2026-06-30	NCT05086692
GI Innovation, Inc.	GI-102 subcutaneous (SC)	—	RECRUITING	2025-11-12	NCT05824975
Simcha IL-18, Inc.	ST-067	—	RECRUITING	2025-06-30	NCT04787042
GeneMedicine Co., Ltd.	GM103 (Part A)	—	RECRUITING	2025-05-30	NCT06265025
Merck	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-07-21	NCT05468697
Inhibrx Biosciences, Inc	INBRX-106 - Hexavalent OX40 agonist antibody	—	ACTIVE NOT RECRUITING	2026-10-30	NCT04198766
Roche	Tobemstomig	—	ACTIVE NOT RECRUITING	2026-10-31	NCT05805501
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-02-26	NCT03634540
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-04-29	NCT03401788
Sensei Biotherapeutics, Inc.	SNS-101 (anti-VISTA)	—	ACTIVE NOT RECRUITING	2027-06	NCT05864144
Roche	Entrectinib	ALK/ROS1/NTRK1/TRKB/TRKC	ACTIVE NOT RECRUITING	2027-06-30	NCT02568267
Merck	Intismeran autogene	—	ACTIVE NOT RECRUITING	2028-01-08	NCT06307431
ImmunityBio, Inc.	N-803 + Pembrolizumab	—	ACTIVE NOT RECRUITING	2029-08-31	NCT03228667
OncoC4, Inc.	ONC-392	—	ACTIVE NOT RECRUITING	2026-06-30	NCT04140526
Adicet Therapeutics	ADI-270	—	ACTIVE NOT RECRUITING	2026-06	NCT06480565
Arsenal Biosciences, Inc.	AB-2100	—	ACTIVE NOT RECRUITING	2026-03-31	NCT06245915
Akeso	AK104	—	ACTIVE NOT RECRUITING	2025-12-31	NCT05256472
Beijing Scitech-Mq Pharmaceuticals Limited	ST-1898 tablets	—	ACTIVE NOT RECRUITING	2025-12	NCT06127238
Salubris Biotherapeutics Inc	JK08	—	ACTIVE NOT RECRUITING	2025-10-17	NCT05620134
Vyriad, Inc.	VSV-IFNβ-NIS	—	ACTIVE NOT RECRUITING	2025-07-31	NCT03647163
ImaginAb, Inc.	zirconium Zr 89 crefmirlimab berdoxam	—	ACTIVE NOT RECRUITING	2025-07	NCT05013099
BeiGene	BGB-A445	—	ACTIVE NOT RECRUITING	2025-05-27	NCT05661955
Merck	Pembrolizumab (+) Berahyaluronidase alfa	—	ACTIVE NOT RECRUITING	2025-04-09	NCT06099782
23andMe, Inc.	23ME-00610	—	ACTIVE NOT RECRUITING	2025-03	NCT05199272
Nimbus Saturn, Inc.	NDI-101150	—	ACTIVE NOT RECRUITING	2025-02	NCT05128487
NGM Biopharmaceuticals, Inc	NGM707	—	ACTIVE NOT RECRUITING	2025-02	NCT04913337
Imbioray (Hangzhou) Biomedicine Co., Ltd.	IBR854	—	NOT YET RECRUITING	2026-12-31	NCT07087158
Regeneron	REGN15505	—	NOT YET RECRUITING	2030-09-20	NCT07594106
VM Discovery, Inc.	VMD-102	—	NOT YET RECRUITING	2031-05	NCT07636785
Kineta Inc.	KVA12123 - Dose Escalation	—	COMPLETED	2025-10-16	NCT05708950
CRISPR Therapeutics AG	CTX131	—	COMPLETED	2025-09-18	NCT05795595
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2025-01-27	NCT04704219
Norroy Bioscience Co., LTD	68Ga-NYM005 injection	—	COMPLETED	2025-01-08	NCT06389682
HUYABIO International, LLC.	HBI-8000 in combination with nivolumab	—	COMPLETED	2023-09	NCT02718066
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	MK-3795	—	COMPLETED	2023-08-30	NCT03108066
Ipsen	Cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	COMPLETED	2023-05-11	NCT03945773
SillaJen, Inc.	Pexastimogene Devacirepvec (Pexa-Vec)	—	COMPLETED	2023-02-16	NCT03294083
Nektar Therapeutics	Dose Escalation Doublet: Combination of NKTR-214 + nivolumab	—	COMPLETED	2022-04-28	NCT02983045
X4 Pharmaceuticals	X4P-001	—	COMPLETED	2022-04-14	NCT02667886
Genocea Biosciences, Inc.	GEN-009 Adjuvanted Vaccine	—	COMPLETED	2021-12-08	NCT03633110
Eisai Inc.	lenvatinib	—	COMPLETED	2021-11-02	NCT02915783
Pharmacyclics LLC.	ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2021-08-20	NCT02599324
Novartis	Pazopanib	—	COMPLETED	2021-08-10	NCT03200717
Incyte Corporation	Retifanlimab	—	COMPLETED	2021-04-15	NCT03679767
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2021-04-01	NCT02089685
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2021-02-05	NCT02853344
Mendus	Intuvax (INN: ilixadencel)	—	COMPLETED	2021-01-31	NCT02432846
Astellas	AGS-16C3F	—	COMPLETED	2020-10-02	NCT02639182
Calithera Biosciences, Inc	CB-839	—	COMPLETED	2020-08-31	NCT03428217
Takeda	Cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	COMPLETED	2020-08-25	NCT03339219
Mirati Therapeutics Inc.	Sitravatinib	—	COMPLETED	2020-04-27	NCT03680521
MedImmune LLC	MEDI0680	—	COMPLETED	2020-03-17	NCT02118337
Eisai Inc.	lenvatinib	—	COMPLETED	2020-02-14	NCT03173560
Millennium Pharmaceuticals, Inc.	Everolimus	Kinase Inhibitor [EPC]	COMPLETED	2020-02-03	NCT02724020
Calithera Biosciences, Inc	CB-839	—	COMPLETED	2019-04-26	NCT03163667
Celldex Therapeutics	Combination of varlilumab and nivolumab	—	COMPLETED	2018-12-12	NCT02335918
Incyte Corporation	MK-3475	—	COMPLETED	2018-11-26	NCT02178722
Eli Lilly	Emibetuzumab	—	COMPLETED	2017-12-05	NCT02082210
Bristol-Myers Squibb	Opdivo	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2017-11-27	NCT03029780
GenSpera, Inc.	G-202	—	COMPLETED	2016-12	NCT02607553
Roche	Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody	—	COMPLETED	2016-10-17	NCT01984242
NewLink Genetics Corporation	CRLX101	—	COMPLETED	2016-07	NCT02187302
Novartis	everolimus	Kinase Inhibitor [EPC]	COMPLETED	2015-05	NCT00903175
Novartis	RAD001	—	COMPLETED	2015-05	NCT01491672
Taiwan Liposome Company	Lipotecan	—	COMPLETED	2015-03-19	NCT01831973
Eisai Inc.	Lenvatinib	—	COMPLETED	2014-06-13	NCT01136733
Intuitive Surgical	—	—	COMPLETED	2013-10	NCT02136121
Bristol-Myers Squibb	nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2013-05-15	NCT01354431
Roche	Everolimus	Kinase Inhibitor [EPC]	COMPLETED	2013-05	NCT01442090
AVEO Pharmaceuticals, Inc.	Tivozanib	—	COMPLETED	2012-10	NCT01297244
Amgen	denosumab	RANK Ligand Inhibitor [EPC]	COMPLETED	2012-09-13	NCT00896454
Argos Therapeutics	AGS-003	—	COMPLETED	2012-05	NCT00678119
GE Healthcare	Fluciclatide Injection	—	COMPLETED	2011-09	NCT00918281
Amgen	Sunitinib	—	COMPLETED	2011-08-08	NCT00853372
Eli Lilly	Enzastaurin	—	COMPLETED	2010-02-15	NCT00709995
Ocellaris Pharma, Inc.	OC-001	—	TERMINATED	2025-11-07	NCT04260802
Genmab	GEN1160	—	TERMINATED	2025-11-05	NCT05721222
NiKang Therapeutics, Inc.	Oral NKT2152	—	TERMINATED	2025-08-22	NCT05119335
NiKang Therapeutics, Inc.	NKT2152	—	TERMINATED	2025-06-30	NCT05935748
Takeda	TAK-500	—	TERMINATED	2025-01-06	NCT05070247
Kymab Limited	Alomfilimab	—	TERMINATED	2024-10-03	NCT03829501
ImaginAb, Inc.	Zirconium 89Zr crefmirlimab berdoxam	—	TERMINATED	2024-05-31	NCT05744128
Incyte Corporation	INCB086550	—	TERMINATED	2024-03-26	NCT04629339
Elevation Oncology	Seribantumab	—	TERMINATED	2024-02-28	NCT04383210
CoImmune	CMN-001	—	TERMINATED	2023-09-28	NCT04203901
Aravive, Inc.	Batiraxcept	—	TERMINATED	2023-08-14	NCT04300140

Showing 100 of 145 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Jiangsu Hansoh Pharmaceutical Co., Ltd.	Oral HS-10516	—	RECRUITING	2026-07-31	NCT06553339
Osel, Inc.	CBM588 Capsules	—	RECRUITING	2026-10-19	NCT06399419
HiberCell, Inc.	HC-7366	—	RECRUITING	2026-11	NCT06234605
Kura Oncology, Inc.	Darlifarnib	—	RECRUITING	2027-01	NCT06026410
Neomorph, Inc	NEO-811	—	RECRUITING	2027-01	NCT07300241
ViroMissile, Inc.	IDOV-Immune (oncolytic vaccinia virus)	—	RECRUITING	2027-01-31	NCT06910657
Xencor, Inc.	XmAb819	—	RECRUITING	2027-02	NCT05433142
Shanghai Henlius Biotech	HLX17	—	RECRUITING	2027-04-30	NCT07160335
Novelty Nobility, Inc.	NN3201	—	RECRUITING	2027-08-30	NCT06805825
KaliVir Immunotherapeutics	VET3-TGI	—	RECRUITING	2027-09-30	NCT06444815
LG Chem	Phase 1a: LB-LR1109	—	RECRUITING	2027-11	NCT06332755
Grit Biotechnology	IB-T101 injection	—	RECRUITING	2027-12-07	NCT06819293
Nammi Therapeutics Inc	QXL138AM Injection every 2 weeks by IV Infusion	—	RECRUITING	2027-12-31	NCT06582017
Chongqing Precision Biotech Co., Ltd	CD70-targeted CAR-T cells	—	RECRUITING	2028-03-31	NCT07181720
Compass Therapeutics	CTX-10726	—	RECRUITING	2028-04-01	NCT07419841
MacroGenics	MGC026 Dose Escalation	—	RECRUITING	2028-05	NCT06242470
AstraZeneca	FPI-2053	—	RECRUITING	2028-05-12	NCT06147037
Deciphera Pharmaceuticals, LLC	DCC-2812	—	RECRUITING	2029-02	NCT06966024
Arcus Biosciences, Inc.	casdatifan	—	RECRUITING	2029-03	NCT05536141
Bristol-Myers Squibb	BMS-986506	—	RECRUITING	2030-05-03	NCT07195682
Exelixis	Zanzalintinib	—	RECRUITING	2030-06-28	NCT05176483
SAPU NANO (US) LLC	Sapu003	—	RECRUITING	2026-06	NCT07369505
Jemincare	JMKX003948	—	RECRUITING	2026-05-31	NCT06321250
Chongqing Precision Biotech Co., Ltd	CD70 CAR-T cells	—	RECRUITING	2025-12-31	NCT06010875
Molecure S.A.	OATD-02	—	RECRUITING	2025-12	NCT05759923
Telix Pharmaceuticals (Innovations) Pty Limited	—	—	RECRUITING	2024-12	NCT05868174
OncoC4, Inc.	AI-061	—	ACTIVE NOT RECRUITING	2026-07-31	NCT05858736
Janux Therapeutics	JANX008	—	ACTIVE NOT RECRUITING	2026-07-31	NCT05783622
Asher Biotherapeutics, Inc.	etakafusp alfa (AB248)	—	ACTIVE NOT RECRUITING	2026-08	NCT05653882
Exelixis	XL092	—	ACTIVE NOT RECRUITING	2026-08-31	NCT03845166
HiFiBiO Therapeutics	HFB200301	—	ACTIVE NOT RECRUITING	2026-12	NCT05238883
HiFiBiO Therapeutics	HFB200603	—	ACTIVE NOT RECRUITING	2026-12	NCT05789069
NeoTX Therapeutics Ltd.	—	—	ACTIVE NOT RECRUITING	2027-03-01	NCT03983954
Nanobiotix	NBTXR3	—	ACTIVE NOT RECRUITING	2027-04-30	NCT03589339
Merck	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-06-30	NCT05030506
Arcus Biosciences, Inc.	AB598	—	ACTIVE NOT RECRUITING	2027-09	NCT05891171
Toray Industries, Inc	TRK-950	—	ACTIVE NOT RECRUITING	2026-06	NCT03872947
Daiichi Sankyo	DS-6000a	—	ACTIVE NOT RECRUITING	2026-04-30	NCT04707248
Poseida Therapeutics, Inc.	P-MUC1C-ALLO1 CAR-T cells	—	ACTIVE NOT RECRUITING	2026-04	NCT05239143
Allogene Therapeutics	ALLO-647	—	ACTIVE NOT RECRUITING	2025-10	NCT04696731
MedImmune LLC	MEDI5752	—	ACTIVE NOT RECRUITING	2025-09-26	NCT04522323
DEKA Biosciences	DK210 (EGFR)	—	ACTIVE NOT RECRUITING	2025-07	NCT05704985
NGM Biopharmaceuticals, Inc	NGM831	—	ACTIVE NOT RECRUITING	2025-07	NCT05215574
RemeGen Co., Ltd.	RC198 Injection	—	ACTIVE NOT RECRUITING	2024-09-30	NCT05867303
Biomica Ltd.	BMC128	—	ACTIVE NOT RECRUITING	2024-05	NCT05354102
Exelixis	cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	ACTIVE NOT RECRUITING	2023-02-21	NCT03170960
Checkpoint Therapeutics, Inc.	CK-301 (cosibelimab)	—	ACTIVE NOT RECRUITING	2021-11-18	NCT03212404
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2018-01-12	NCT02974738
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	MK-3795	—	ACTIVE NOT RECRUITING	2017-01-31	NCT02293980
AccSalus Biosciences, Inc.	ACC-1898	—	NOT YET RECRUITING	2027-06	NCT07252661
Huahui Health	HH160	—	NOT YET RECRUITING	2028-08	NCT07623369
Hrain Biotechnology Co., Ltd.	Anti-Human CD70 T-Cell Injection	—	NOT YET RECRUITING	2029-06	NCT07647744
Mabpro, a.s.	CA9hu-1	—	NOT YET RECRUITING	2026-01	NCT05698238
Philogen S.p.A.	[68Ga]Ga-OncoCAIX	—	COMPLETED	2025-11-28	NCT06840548
MacroGenics	vobramitamab duocarmazine	—	COMPLETED	2025-06-24	NCT05293496
Coherus Oncology, Inc.	CHS-388	—	COMPLETED	2025-05-28	NCT04374877
Celldex Therapeutics	CDX-585	—	COMPLETED	2025-05-21	NCT05788484
Xencor, Inc.	XmAb®808	—	COMPLETED	2025-05-20	NCT05585034
Xencor, Inc.	XmAb®23104	—	COMPLETED	2024-02-15	NCT03752398
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2024-01-18	NCT04540705
HiberCell, Inc.	HC-5404-FU	—	COMPLETED	2023-12-07	NCT04834778
Telix Pharmaceuticals (Innovations) Pty Limited	89Zr-Girentuximab	—	COMPLETED	2023-11-27	NCT05861778
Mirati Therapeutics Inc.	Sitravatinib	—	COMPLETED	2023-06-30	NCT04518046
Shattuck Labs, Inc.	SL-279252	—	COMPLETED	2023-05-04	NCT03894618
Celldex Therapeutics	CDX-527	—	COMPLETED	2023-04-06	NCT04440943
Novartis	Gevokizumab	—	COMPLETED	2023-03-01	NCT03798626
Xencor, Inc.	XmAb®22841	—	COMPLETED	2023-02-16	NCT03849469
Fate Therapeutics	FT500	—	COMPLETED	2022-11-15	NCT03841110
Quadriga Biosciences, Inc.	QBS10072S	—	COMPLETED	2022-09-21	NCT04430842
Celldex Therapeutics	CDX-1140	—	COMPLETED	2022-09-13	NCT03329950
Tempest Therapeutics	Part 1 TPST-1120	—	COMPLETED	2022-09-07	NCT03829436
Xencor, Inc.	XmAb20717	—	COMPLETED	2022-06-01	NCT03517488
Arrowhead Pharmaceuticals	ARO-HIF2	—	COMPLETED	2022-01-24	NCT04169711
Arcus Biosciences, Inc.	Etrumadenant	—	COMPLETED	2021-08-18	NCT03629756
Incyte Corporation	INCAGN02390	—	COMPLETED	2021-08-18	NCT03652077
Evelo Biosciences, Inc.	EDP1503	—	COMPLETED	2021-06-30	NCT03775850
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2021-06-14	NCT03063762
Telix Pharmaceuticals (Innovations) Pty Limited	—	—	COMPLETED	2020-10-27	NCT04496089
Incyte Biosciences International Sàrl	INCAGN02385	—	COMPLETED	2020-10-07	NCT03538028
Fate Therapeutics	FATE-NK100	—	COMPLETED	2020-05-29	NCT03319459
Incyte Corporation	INCB001158	—	COMPLETED	2020-04-30	NCT02903914
Five Prime Therapeutics, Inc.	Cabiralizumab	—	COMPLETED	2019-11-18	NCT02526017
Incyte Corporation	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2019-11-07	NCT02646748
MacroGenics	MGA271	—	COMPLETED	2019-04-18	NCT01391143
Calithera Biosciences, Inc	CB-839	—	COMPLETED	2019-03	NCT02071862
Eli Lilly	Pegilodecakin	—	COMPLETED	2019-02-19	NCT02009449
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Sunitinib malate capsules generic product	—	COMPLETED	2019-01-06	NCT05800106
Cancer Targeted Technology	CTT1057	—	COMPLETED	2018-08-31	NCT03427476
Sumitomo Pharma America, Inc.	DSP-7888 Dosing Emulsion	—	COMPLETED	2018-08	NCT02498665
Bristol-Myers Squibb	CC-486	—	COMPLETED	2018-06-11	NCT02223052
Pfizer	Axitinib	Kinase Inhibitor [EPC]	COMPLETED	2017-03-31	NCT02133742
Agensys, Inc.	AGS-16C3F	—	COMPLETED	2017-02-21	NCT01672775
Seagen Inc.	SGN-CD70A	—	COMPLETED	2017-02-15	NCT02216890
NewLink Genetics Corporation	HyperAcute®-Renal (HAR) Immunotherapy	—	COMPLETED	2017-01-03	NCT02035358
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2016-02-02	NCT01472081
Akamis Bio	Colo-Ad1	—	COMPLETED	2015-04	NCT02053220
Novartis	RAD001 + BEZ235	—	COMPLETED	2015-02	NCT01482156
Bristol-Myers Squibb	BMS-936558 (Anti-PD-1)	—	COMPLETED	2014-12-01	NCT01358721
Amgen	AMG 172	—	COMPLETED	2014-11	NCT01497821
Novartis	Everolimus (RAD001)	—	COMPLETED	2013-12	NCT01152801

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Renal Cell Carcinoma

VEGF (17) RET (12) ROS1 (11) FLT3 (10) EGFR- (8) FGFR (8)

Novel Renal Cell Carcinoma Drugs by Company (New molecular entities)

5 companies have an FDA-approved novel drug for Renal Cell Carcinoma.

Bristol-Myers Squibb 3 drugs

Merck 2 drugs

Roche 1 drug

CHIRON 1 drug

AVEO PHARMS 1 drug

TIVOZANIB HYDROCHLORIDE

NDA 2021

Reformulations (3 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Renal Cell Carcinoma Drug Targets

Molecular targets of approved and investigational Renal Cell Carcinoma drugs — 34 targets tracked.

FKBP-12 4 mTOR 4 VEGFA 4 KIT 3 VEGFR-1 3 VEGFR-2 3 VEGFR-3 3 PDCD1 3 RET 2 FGFR-1 1 FGFR-3 1 Itk 1 LCK 1 PDGFR-α 1 PDGFR-β 1 +19 more

Biosimilars (4 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

AVZIVI

BIO-THERA SOLUTIONS LTD

2017